Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22118770 | 0.86 | BRD4 (0.40) | MKNK1BRD4PARP1BRAFEGFR | |
| SCHEMBL29654971 | 0.86 | BRD4 (0.40) | MKNK1BRD4PARP1BRAFEGFR | |
| SCHEMBL536914 | 0.84 | BRAF (0.47) | MKNK1BRD4BRAFGDANPC1 | |
| SCHEMBL17778780 | 0.80 | XDH (0.42) | BRD4BRAFEGFRNPC1RAB9A | |
| SCHEMBL67930 | 0.80 | JAK3 (0.39) | EGFR | |
| SCHEMBL19699540 | 0.80 | GSK3B (0.38) | BRD4BRAFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8884122 | 0.80 | L3MBTL1 (0.38) | BRD4BRAFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1369225 | 0.79 | XDH (0.41) | MKNK1BRD4PARP1BRAFNT5C2 | |
| SCHEMBL18259658 | 0.78 | TP53 (0.41) | MKNK1BRD4PARP1GDASMN1; SMN2 | |
| SCHEMBL19735835 | 0.78 | BRD4 (0.33) | MKNK1BRD4BRAFNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183319-B2 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY | 2007-02-27 | — | — | US | disclosed |
| US-20040029967-A1 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY (GB) | 2004-02-12 | — | — | US | disclosed |
| EP-1303481-A1 | PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA | Riley, Patrick Anthony (GB) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002008174-A1 | PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA | RILEY PATRICK ANTHONY (GB) | 2002-01-31 | — | — | WO | disclosed |
| WO-1994006438-A1 | ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-31 | — | — | WO | disclosed |
| US-4038480-A | HYPOTENSIVE AGENTS;INCREASE CARDIAC OUTPUT;ENZYME ACTIVATORS | ICN PHARMACEUTICALS, INC. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029967-A1 | Phenylethylamine derivatives and their use in the treatment of melanoma | DOHH, DBH, HRH4 | MKNK1 4301/4885BRD4 1268/4885PARP1 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.